Zevra Therapeutics

ZVRA · NASDAQ

$10.47+$0.31 (+3.05%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $10.16

ZVRA analyst rating

BuyConsensus of 8 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy8
Hold0
Underperform0
Sell0

12-month price target · 10 analysts

Average $25.75 (+146.0% upside)

Low: $20.20
Now: $10.47
High: $36.75

Upgrades and downgrades

The latest rating actions, newest first

ZVRA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Aug 20, 2026	Maintains	Buy	$26.00	36%
Guggenheim	Aug 7, 2026	Maintains	Buy	$24.00 → $23.00	52%
Citizens	Aug 6, 2026	Maintains	Market Outperform	$25.00 → $28.00	41%
Canaccord Genuity	Jul 27, 2026	Maintains	Buy	$29.00 → $20.00	42%
Guggenheim	Jul 27, 2026	Maintains	Buy	$29.00 → $24.00	52%
BTIG	Jul 27, 2026	Maintains	Buy	$27.00 → $24.00	20%
HC Wainwright & Co.	Jun 23, 2026	Maintains	Buy	$26.00	36%
Canaccord Genuity	Jun 11, 2026	Maintains	Buy	$29.00	42%
Maxim Group	Jun 10, 2026	Maintains	Buy	$25.00 → $35.00	27%
Guggenheim	Jun 10, 2026	Maintains	Buy	$25.00 → $29.00	52%

The case for and against

Updated Oct 15, 2026

Bull case

Zevra Therapeutics is attractive because its U.S. MIPLYFFA launch is proving durable, with 184 cumulative prescription enrollment forms through 2Q26, 14 new starts in 2Q26, and $30.2MM in U.S. net sales, while payor access remains stable at 69% of covered lives. The company’s commercial strategy is increasingly effective at finding previously undiagnosed NPC patients across pediatric and adult segments, supporting a longer runway than the currently diagnosed 300–350 U.S. patient pool and the broader ~900-patient estimate suggests. With about $260M of cash and investments, no debt, 2041 patent protection, and optionality in Europe and celiprolol, the company has both financial flexibility and multiple pathways to incremental value creation.

Bear case

Zevra Therapeutics is viewed negatively because its revenue outlook is being pressured by volatility in the timing and size of non-French EAP reimbursements, which has forced lower near-term ROW/EAP estimates despite commercialization progress for Miplyffa. The stock also faces meaningful execution risk from a recent competitor approval, possible payer preference for that rival, and emerging safety or tolerability issues that could slow launch ramp, raise discontinuations, and reduce peak sales potential. Fundamentally, the company remains exposed to clinical, regulatory, litigation, and balance-sheet risk, with a history of losses and a likely need to raise additional capital to support its long-term commercial strategy.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.